Progress of computer-aided drug design (CADD) of proteasome inhibitors

Current Topics in Medicinal Chemistry

Volumn 11, Issue 23, 2011, Pages 2931-2944

  Lei, Meng ^a   Liu, Yunde ^a   Zhu, Yongqiang ^a   Liu, Zhenming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Computer aided drug design; Proteasome inhibitor; Rational drug design

Indexed keywords

APIGENIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; ELLAGIC ACID; GALLIC ACID; GENISTEIN; GREEN TEA EXTRACT; KAEMPFEROL; LUTEOLIN; MYRICETIN; PROTEASOME INHIBITOR; QUERCETIN; RESVERATROL; STATINE 1; STATINE 2; THREONINE PROTEINASE INHIBITOR; TP 101; TP 102; TP 103; TP 104; TP 105; TP 106; TP 107; TP 108; TP 109; TP 110; TP 111; TYROPEPTIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPUTER AIDED DRUG DESIGN; COMPUTER PROGRAM; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; HUMAN; IC 50; MOLECULAR DOCKING; NONHUMAN; STRUCTURE ACTIVITY RELATION; TEA;

EID: 83455203249     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798281366     Document Type: Article

References (96)

1. Whittle, P.; Blundell, T. Protein structure-based drug design. Annu. Rev. Bioph. Biom., 1994, 23, 349-375.
2. Brooijmans, N.; Kuntz, I. D. Molecular recognition and docking algorithms. Annu. Rev. Bioph. Biom., 2003, 32, 335-373.
3. Gupta, S. P. QSAR studies on enzyme inhibitors. Chem. Rev., 1987, 87, 1183-1253.
4. Gupta, S. P.; Scient, J. QSAR in design of bioactive compounds. Indus. Res., 1991, 50, 301-310.
5. Ciechanover, A.; Orian, A.; Schwartz, A. L. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays, 2000, 22, 442-451.
6. Sakamoto, K. M. Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Mol. Genet. Metab., 2002, 77, 44-56.
7. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol., 2001, 8, 739-758.
8. Coux, O.; Tanaka, K.; Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem., 1996, 65, 801-847.
9. Rechsteiner, M.; Hill, C. P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. TRENDS Cell Biol., 2005, 15, 27-33.
10. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature, 2003, 426, 895-899.
11. Zolk, O.; Schenke, C.; Sarikas, A. The ubiquitin-proteasome system: focus on the heart. Cardiovasc. Res., 2006, 70, 410-421.
12. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem., 1998, 67, 425-479.
13. Hochstrasser, M. Ubiquitin-dependent protein degradation. Annu. Rev. Genet., 1996, 30, 405-439.
14. Löwe, J.; Stock, D.; Jap, B.; Zwickl, P.; Baumeister, W.; Huber, R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 Å resolution. Science, 1995, 268, 533-539.
15. Groll, M.; Ditzel, L.; Löwe, J.; Stock, D.; Bochtler, M. B.; Huber, R. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature (London), 1997, 386, 463-471.
16. Brannigan, J. A.; Dodson, G.; Duggleby, H. J.; Moody, P. C.; Smith, J. L.; Tomchick, D. R.; Murzin, A. G. A protein catalytic framework with an N-terminal nucleophile is capable of selfactivation. Nature (London), 1995, 378, 416-419.
17. Schubert, U.; Anton, L. C.; Gibbs, J.; Norbury, C. C.; Yewdell, J. W.; Bennink, J. R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (London), 2000, 404, 770-774.
18. Larsen, C. N.; Finley, D. Protein translocation channels in the proteasome and other proteases. Cell, 1997, 91, 431-434.
19. Baumeister, W.; Walz, J.; Zühl, F.; Seemüller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell, 1998, 92, 367-380.
20. Kloetzel, P. M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol., 2001, 2, 179-187.
21. Rock, A. L.; Goldberg, K. L. Degradation of cell proteins and the generation of MHC class I- presented peptides. Annu. Rev. Immunol., 1999, 17, 739-779.
22. Deng, G. Y.; Muir, A.; Maclaren, N. K.; She, J. X. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: Population family studies. Am. J. Hum. Genet., 1995, 56, 528-534.
23. Diaz-Hernandez, M.; Hernandez, F.; Martin-Aparicio, E.; Gomez-Ramos, P.; Moran, M. A.; Castano, J. G.; Ferrer, I.; Avila, J.; Lucas, J. J. Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci., 2003, 23, 11653-11661.
24. Mishto, M.; Bellavista, E.; Santoro, A.; Stolzing, A.; Ligorio, C.; Nacmias, B.; Spazzafumo, L.; Chiappelli, M.; Licastro, F.; Sorbi, S.; Pession, A.; Ohm, T.; Grune, T.; Franceschi, C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol. Aging, 2006, 27, 54-66.
25. Piccinini, M.; Mostert, M.; Croce, S.; Baldovino, S.; Papotti, M.; Rinaudo, M. T. Interferon-γ-inducible subunits are incorporated in human brain 20S proteasome. J. Neuroimmunol., 2003, 135, 135-140.
26. Voorhees, P. M.; Orlowski, R. Z. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 189-213.
27. Casp, C. B.; She, J. X.; McCormack, W. T. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes. Immun., 2003, 4, 492-499.
28. Delcros, J. G.; Baudy Floc'h, M.; Prigent, C.; Arlot-Bonnemains, Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Curr. Med. Chem., 2003, 10, 479-503.
29. Ho, A.; Cyrus, K.; Kim, K. B. Towards immunoproteasomespecific inhibitors: an improved synthesis of dihydroeponemycin. Eur. J. Org. Chem., 2005, 4829-4834.
30. Kuhn, D. J.; Hunsucker, S. A.; Chen, Q.; Voorhees, P. M.; Orlowski, M.; Orlowski, R. Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 2009, 113, 4667-4676.
31. Ahtoniemi, T.; Goldsteins, G.; Keksa-Goldsteine, V.; Malm, T.; Kanninen, K.; Salminen, A.; Koistinaho, J. Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol. Pharmacol., 2007, 71, 30-37.
32. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehu, D.; Lonial, S.; Goldschmidt, H. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 2005, 352, 2487-2498.
33. Orlowski, R. Z.; Zeger, E. L. Targeting the proteasome as a therapeutic strategy against hematological malignancies. Expert Opin. Invest. Drugs, 2006, 15, 117-130.
34. Thomson-pharma Database. https://www.thomson-pharma.com/ [Accessed December 2009].
35. Chauhan, D.; Hideshima, T.; Anderson, K. C. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 465-476.
36. Ohno, Y.; Wakai, K.; Genka, K.; Ohmine, K.; Kawamura, T.; Tamakoshi, A.; Aoki, R.; Senda, M.; Hayashi, Y.; Nagao, K.; Fukuma, S.; Aoki, K. Tea consumption and lung cancer risk: a casecontrol study in Okinawa, Japan. Jpn. J. Cancer Res., 1995, 86, 1027-1034.
37. Zhong, L.; Goldberg, M. S.; Gao, Y. T.; Hanley, J. A.; Parent, M. E.; Jin, F. A population based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology, 2001, 12, 695-700.
38. Ji, B. T.; Chow, W. H.; Hsing, A. W.; McLaughlin, J. K.; Dai, Q.; Gao, Y. T.; Blot, W. J.; Fraumeni, J. F. Jr. Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer, 1997, 70, 255-258.
39. Inoue, M.; Tajima, K.; Mizutani, M.; Iwata, H.; Iwase, T.; Miura, S.; Hirose, K.; Hamajima, N.; Tominaga, S. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett., 2001, 167, 175-182.
40. Taniguchi, S.; Fujiki, H.; Kobayashi, H.; Go, H.; Miyado, K.; Sadano, H.; Shimokawa, R. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett., 1992, 65, 51-54.
41. Wang, Z. Y.; Huang, M. T.; Ho, C. T.; Chang, R.; Ma, W.; Ferraro, T.; Reuhl, K. R.; Yang, C. S.; Conney, A. H. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res., 1992, 52, 6657-6665.
42. Liao, S.; Umekita, Y.; Guo, J.; Kokontis, J. M.; Hiipakka, R. A. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett., 1995, 96, 239-243.
43. Gupta, S.; Ahmad, N.; Mohan, R. R.; Husain, M. M; Mukhtar, H. Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone- mediated induction of ornithine decarboxylase. Cancer Res., 1999, 59, 2115-2120.
44. Muto, S.; Yokoi, T.; Gondo, Y.; Katsuki, M.; Shioyama, Y.; Fujita, K.; Kamataki, T. Inhibition of benzo[a]pyrene-induced mutagenesis by (-)-epigallocatechin gallate in the lung of rpsL transgenic mice. Carcinogenesis, 1999, 20, 421-424.
45. Nam, S.; Smith, D. M.; Dou, Q. P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 2001, 276, 13322-13330.
46. Smith, D. M.; Wang, Z.; Kazi, A.; Li, L. H.; Chan, T. H.; Dou, Q. P. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol. Med., 2002, 8, 382-392.
47. Smith, D.M.; Daniel, K. G.; Wang, Z. G.; Guida, W. C.; Chan, T. H.; Dou, Q. P. Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design. Proteins: Structure, Function, and Bioinformatics. 2004, 54, 58-70.
48. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res., 2000, 28, 235-242.
49. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
50. Chen, D.; Daniel, K. G.; Chen, M. S.; Kuhn, D. J.; Landis-Piwowar, K. R.; Dou, Q. P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol., 2005, 69, 1421-1432.
51. Ueda, H.; Yamazaki, C.; Yamazaki, M. A hydroxyl group of flavonoids affects oral anti-inflammatory activity and inhibition of systemic tumor necrosis factor-alpha production. Biosci. Biotechnol. Biochem., 2004, 1, 119-125.
52. Mozzicafreddo, M.; Cuccioloni, M.; Cecarini, V.; Eleuteri, A. M.; Angeletti, M. Homology modeling and docking analysis of the interaction between polyphenols and mammalian 20S proteasomes. J. Chem. Inf. Model., 2009, 49, 401-409.
53. Krieger, E.; Nabuurs, S. B.; Vriend, G. Homology modeling. Methods Biochem. Anal., 2003, 44, 509-523.
54. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M. C. Swiss-Model: An automated protein homology-modeling server. Nucleic Acids Res., 2003, 31, 3381-3385.
55. Unno, M.; Mizushima, T.; Morimoto, Y.; Tomisugi, Y.; Tanaka, K.; Yasuoka, N.; Tsukihara, T. The structure of the mammalian 20S proteasome at 2.75 Å resolution. Structure, 2002, 10, 609-618.
56. Groll, M.; Bajorek, M.; Kohler, A.; Moroder, L.; Rubin, D. M.; Huber, R.; Glickman, M. H.; Finley, D. A gated channel into the proteasome core particle. Nat. Struct. Biol., 2000, 7, 1062-1067.
57. Groll, M.; Kim, K. B.; Kairies, N.; Crews, C. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha, beta- epoxyketone proteasome inhibitors. J. Am. Chem. Soc., 2000, 122, 1237-1238.
58. Groll, M.; Berkers, C. R.; Ploegh, H. L.; Ovaa, H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure, 2006, 14, 451-456.
59. Groll, M.; Huber, R.; Potts, B. C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J. Am. Chem. Soc., 2006, 128, 5136-5141.
60. Groll, M.; Koguchi, Y.; Huber, R.; Kohno, J. Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J. Mol. Biol., 2001, 311, 543-548.
61. Forster, A.; Masters, E. I.; Whitby, F. G.; Robinson, H.; Hill, C. P. The 1.9 Å structure of a proteasome-11S activator complex and implications for proteasome-PAN/PA700 interactions. Mol. Cell, 2005, 18, 589-599.
62. Release 2005, Accelrys Ltd., Cambridge, U.K.
63. Kuhn, D. J.; Burns, A. C.; Kazi, A.; Dou, Q. P. Direct inhibition of the ubiquitin- proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor. Biochim. Biophys. Acta, 2004, 1682, 1-10.
64. Momose, I.; Sekizawa, R.; Hashizume, H.; Kinoshita, N.; Homma, Y.; Hamada, M.; Iinuma, H.; Takeuchi, T. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. I. Taxonomy, isolation, physico-chemical properties and biological activities. J. Antibiot., 2001, 54, 997-1003.
65. Momose, I.; Sekizawa, R.; Hirosawa, S.; Ikeda, D.; Naganawa, H.; Iinuma, H.; Takeuchi, T. Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2. II. Structure determination and synthesis. J. Antibiot., 2001, 54, 1004-1012.
66. Momose, I.; Sekizawa, R.; Iinuma, H.; Takeuchi, T. Inhibition of proteasome activity by tyropeptin A in PC12 cells. Biosci. Biotechnol. Biochem., 2002, 54, 2256-2258.
67. Momose, I.; Umezawa, Y.; Hirosawa, S.; Iinuma, H.; Ikeda, D. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med. Chem. Lett., 2005, 15, 1867-1871.
68. Unno, M.; Mizushima, T.; Morimoto, Y.; Tomisugi, Y.; Tanaka, K.; Yasuoka, N.; Tsukihara, T. Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 Å resolution. J. Biochem. (Tokyo), 2002, 131, 171-173.
69. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun., 1967, 27, 157-162.
70. Umezawa, Y.; Nishio, M. CH/l{cyrillic} interactions as demonstrated in the crystal structure of guanine-nucleotide binding proteins, Src homology-2 domains and human growth hormone in complex with their specific ligands. Bioorg. Med. Chem., 1998, 6, 493-504.
71. Vinitsky, A.; Michaud, C.; Powers, J. C.; Orlowski, M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 1992, 31, 9421-9428.
72. Rock, K. L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class 1 molecules. Cell, 1994, 78, 761-771.
73. Tsubuki, S.; Saito, Y.; Tomioka, M.; Ito, H.; Kawashima, S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-Leucine and tri-Leucine. J. Biochem., 1996, 119, 572-576.
74. Palombella, V. J.; Rando, O. J.; Goldberg, A. L.; Maniatis, T. The ubiquitin- proteosome pathway is required for processing the NFkB1 precursor protein and the activation of NF-kB. Cell, 1994, 78, 773-785.
75. Zhang, S. W.; Shi, Y. W.; Jin, H. W.; Liu, Z. M.; Zhang, L. R.; Zhang, L. H. Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study. J. Mol. Model., 2009, 15, 1481-1490.
76. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 1997, 267, 727-748.
77. The Cambridge Crystallographic Data Centre GOLD 4.0, 609 CCDC, Cambridge, UK. 2008.
78. Zhu, Y. Q.; Pei, J. F.; Liu, Z. M.; Lai, L. H.; Cui, J. R.; Li, R. T. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods. Bioorg. Med. Chem., 2006, 14, 1483-1496.
79. Stain, R. L. Inhibitors of the 26S proteolytic complex and the 20S proteasome contained therein. U.S. Patent 5,693,617, December 2, 1997.
80. Rydzewski, R. M.; Burrill, L.; Mendonca, R.; Palmer, J. T.; Rice, M.; Tahilramani, R.; Bass, K. E.; Leung, L.; Gjerstad, E.; Janc, J. W.; Pan, L. Optimization of subsite binding to the β5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors. J. Med. Chem., 2006, 49, 2953-2968.
81. Fu, Y. Q.; Xu, B.; Zou, X. M.; Ma, C.; Yang, X. M.; Mou, K.; Fu, G.; Lü, Y.; Xu, P. Design and synthesis of a novel class of furanbased molecules as potential 20S proteasome inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 1102-1106.
82. Mou, K.; Xu, B.; Ma, C.; Yang, X. M.; Zou, X. M.; Lü, Y.; Xu, P. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 2198-2202.
83. Furet, P.; Imbach, P.; Fürst, P.; Lang, M.; Noorani, M.; Zimmermann, J.; García-Echeverría, C. Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. Bioorg. Med. Chem. Lett., 2001, 11, 1321-1324.
84. Vriend, G. WHAT IF: a molecular modeling and drug design program. J. Mol. Graph., 1990, 8, 52-56.
85. García-Echeverría, C.; Imbach, P.; France, D.; Fürst, P.; Lang, M.; Noorani, M.; Scholz, D.; Zimmermann, J.; Furet, P. A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome. Bioorg. Med. Chem. Lett., 2001, 11, 1317-1319.
86. Kubinyi, H. QSAR and 3D QSAR in drug design Part 1: methodology. Drug Discov. Today, 1997, 2, 457-467.
87. Tripos Inc., St. Louis, USA, version 7.3.
88. Zhu, Y. Q.; Yao, S. Y; Xu, B.; Ge, Z. M.; Cui, J. R.; Chen, T. M.; Li, R. T. Design, synthesis and biological evaluation of tripeptide boronic acid proteasome inhibitors. Bioorg. Med. Chem., 2009, 17, 6851-6861.
89. Adams, J.; Ma, Y. T.; Stein, R.; Baevsky, M.; Grenier, L.; Plamonda, L. PCT Int. Appl.,WO 1996013266, September 5, 1995.
90. Zhu, Y. Q.; Lei, M.; Lu, A. J.; Zhao, X.; Yin, X. J.; Gao, Q. Z. 3DQSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods. Eur. J. Med. Chem., 2009, 44, 1486-1499.
91. Johnsamuel, J.; Byun, Y.; Jones, T. P.; Endo, Y.; Tjarks, W. A new strategy for molecular modeling and receptor-based design of carborane containing compounds. J. Organomet. Chem., 2003, 680, 223-231.
92. Johnsamuel, J.; Byun, Y.; Jones, T. P.; Endo, Y.; Tjarks, W. A convenient method for the computer-aided molecular design of carborane containing compounds. Bioorg. Med. Chem. Lett., 2003, 13, 3213-3216.
93. Zhu, Y. Q.; Zhao, X.; Zhu, X. R; Wu, G.; Li, Y. J.; Ma, Y. H.; Yuan, Y. X.; Yang, J.; Hu, Y.; Ai, L.; Gao, Q. Z. Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of α-amino acid boronates. J. Med. Chem., 2009, 52, 4192-4199.
94. Lei, M.; Zhao, X.; Wang, Z. L.; Zhu, Y. Q. Pharmacophore modeling, docking studies and synthesis of novel dipeptide proteasome inhibitors containing boron atoms. J. Chem. Inf. Mol., 2009, 49, 2092-2100.
95. Catalyst, 4.11; Accelrys Inc.: San Diego, CA, USA.
96. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev., 2007, 107, 687-717.